J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
AbbVie/Janssen win EU approval for two new Imbruvica usesEuropean regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of Share XAbbVie/Janssen win EU approval for two new Imbruvica useshttps://pharmaphorum.com/news/eu-regulators-approve-two-new-uses-for-janssens-imbruvica/
Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Mesoblast poised to file cell therapy for GVHD in USAustralian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute Share XMesoblast poised to file cell therapy for GVHD in UShttps://pharmaphorum.com/news/mesoblast-cell-therapy-gvhd-fda/
Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOIt has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership Share XGilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOhttps://pharmaphorum.com/news/gilead-expands-car-t-deal-with-maxcyte-precision-files-for-100m-ipo/
Sanofi’s Darzalex rival hits the mark in phase 3 trialJohnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition Share XSanofi’s Darzalex rival hits the mark in phase 3 trialhttps://pharmaphorum.com/news/sanofis-darzalex-rival-hits-the-mark-in-phase-3-trial/
Oncology round-up: CAR-T conference raises hopes for solid tumour therapyKisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it Share XOncology round-up: CAR-T conference raises hopes for solid tumour therapyhttps://pharmaphorum.com/views-and-analysis/oncology-round-up-car-t-conference-raises-hopes-for-solid-tumour-therapy/
Doctors and patient groups struggle with CAR-T ‘hype’Managing patients’ expectations of CAR-T therapies is proving to be a huge challenge from when selection decisions are Share XDoctors and patient groups struggle with CAR-T ‘hype’https://pharmaphorum.com/news/doctors-and-patient-groups-struggle-with-car-t-hype/
CAR-T firms push to improve manufacturing efficiencyExperience with the approved CAR-T drugs from Novartis and Gilead has shown that being able to manufacture enough Share XCAR-T firms push to improve manufacturing efficiencyhttps://pharmaphorum.com/news/car-t-firms-push-to-improve-manufacturing-efficiency/
